<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Recce Ltd — News on 6ix</title>
<link>https://6ix.com/company/recce-ltd</link>
<description>Latest news and press releases for Recce Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 24 Mar 2026 05:13:03 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/recce-ltd" rel="self" type="application/rss+xml" />
<item>
<title>Brazil Patent Granted for RECCE Anti-Infectives</title>
<link>https://6ix.com/company/recce-ltd/news/brazil-patent-granted-for-recce-anti-infectives</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/brazil-patent-granted-for-recce-anti-infectives</guid>
<pubDate>Tue, 24 Mar 2026 05:13:03 GMT</pubDate>
<description>Brazil Patent Granted for RECCE Anti-Infectives</description>
</item>
<item>
<title>RCE Investor Webinar Presentation Deck</title>
<link>https://6ix.com/company/recce-ltd/news/rce-investor-webinar-presentation-deck</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/rce-investor-webinar-presentation-deck</guid>
<pubDate>Thu, 19 Mar 2026 04:04:03 GMT</pubDate>
<description>RCE Investor Webinar Presentation Deck</description>
</item>
<item>
<title>Appendix 4D and Interim Financial Report</title>
<link>https://6ix.com/company/recce-ltd/news/appendix-4d-and-interim-financial-report-46</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/appendix-4d-and-interim-financial-report-46</guid>
<pubDate>Fri, 27 Feb 2026 12:23:15 GMT</pubDate>
<description>Appendix 4D and Interim Financial Report</description>
</item>
<item>
<title>Recce Enters Second U.S. Department of Defense R&D Agreement</title>
<link>https://6ix.com/company/recce-ltd/news/recce-enters-second-us-department-of-defense-randd-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/recce-enters-second-us-department-of-defense-randd-agreement</guid>
<pubDate>Mon, 02 Feb 2026 03:19:06 GMT</pubDate>
<description>Recce Enters Second U.S. Department of Defense R&D Agreement</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/recce-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-52</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-52</guid>
<pubDate>Fri, 30 Jan 2026 07:22:04 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>AUD $5.3m R&D Rebate Received</title>
<link>https://6ix.com/company/recce-ltd/news/aud-dollar53m-randd-rebate-received</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/aud-dollar53m-randd-rebate-received</guid>
<pubDate>Wed, 14 Jan 2026 04:57:03 GMT</pubDate>
<description>AUD $5.3m R&D Rebate Received</description>
</item>
<item>
<title>RCE Awarded Advanced Overseas Finding up to A$85m</title>
<link>https://6ix.com/company/recce-ltd/news/rce-awarded-advanced-overseas-finding-up-to-adollar85m</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/rce-awarded-advanced-overseas-finding-up-to-adollar85m</guid>
<pubDate>Tue, 16 Dec 2025 04:09:13 GMT</pubDate>
<description>RCE Awarded Advanced Overseas Finding up to A$85m</description>
</item>
<item>
<title>Hong Kong Patent Granted for RECCE Anti-Infectives</title>
<link>https://6ix.com/company/recce-ltd/news/hong-kong-patent-granted-for-recce-anti-infectives</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/hong-kong-patent-granted-for-recce-anti-infectives</guid>
<pubDate>Thu, 27 Nov 2025 04:26:03 GMT</pubDate>
<description>Hong Kong Patent Granted for RECCE Anti-Infectives</description>
</item>
<item>
<title>Positive Efficacy Data for Inhaled R327 in HAP/VAP Model</title>
<link>https://6ix.com/company/recce-ltd/news/positive-efficacy-data-for-inhaled-r327-in-hapvap-model</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/positive-efficacy-data-for-inhaled-r327-in-hapvap-model</guid>
<pubDate>Wed, 26 Nov 2025 04:11:04 GMT</pubDate>
<description>Positive Efficacy Data for Inhaled R327 in HAP/VAP Model</description>
</item>
<item>
<title>Patient Dosing Underway in Ph 3 Indonesia DFI Trial</title>
<link>https://6ix.com/company/recce-ltd/news/patient-dosing-underway-in-ph-3-indonesia-dfi-trial</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/patient-dosing-underway-in-ph-3-indonesia-dfi-trial</guid>
<pubDate>Thu, 25 Sep 2025 04:10:11 GMT</pubDate>
<description>Patient Dosing Underway in Ph 3 Indonesia DFI Trial</description>
</item>
<item>
<title>Preliminary Final Report</title>
<link>https://6ix.com/company/recce-ltd/news/preliminary-final-report-152</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/preliminary-final-report-152</guid>
<pubDate>Fri, 29 Aug 2025 13:48:13 GMT</pubDate>
<description>Preliminary Final Report</description>
</item>
<item>
<title>R327G Highly Effective in Burn Wounds Model</title>
<link>https://6ix.com/company/recce-ltd/news/r327g-highly-effective-in-burn-wounds-model</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/r327g-highly-effective-in-burn-wounds-model</guid>
<pubDate>Tue, 12 Aug 2025 05:14:11 GMT</pubDate>
<description>R327G Highly Effective in Burn Wounds Model</description>
</item>
<item>
<title>Recce Signs Debt Facility with Avenue Capital Group</title>
<link>https://6ix.com/company/recce-ltd/news/recce-signs-debt-facility-with-avenue-capital-group</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/recce-signs-debt-facility-with-avenue-capital-group</guid>
<pubDate>Tue, 17 Jun 2025 04:50:09 GMT</pubDate>
<description>Recce Signs Debt Facility with Avenue Capital Group</description>
</item>
<item>
<title>Successful Placement of Entitlement Offer Shortfall</title>
<link>https://6ix.com/company/recce-ltd/news/successful-placement-of-entitlement-offer-shortfall</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/successful-placement-of-entitlement-offer-shortfall</guid>
<pubDate>Tue, 03 Jun 2025 04:19:13 GMT</pubDate>
<description>Successful Placement of Entitlement Offer Shortfall</description>
</item>
<item>
<title>China Patent Accepted for RECCE Anti-Infectives</title>
<link>https://6ix.com/company/recce-ltd/news/china-patent-accepted-for-recce-anti-infectives</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/china-patent-accepted-for-recce-anti-infectives</guid>
<pubDate>Mon, 26 May 2025 05:20:08 GMT</pubDate>
<description>China Patent Accepted for RECCE Anti-Infectives</description>
</item>
<item>
<title>Recce Enters into USA Department of Defense R&D Agreement</title>
<link>https://6ix.com/company/recce-ltd/news/recce-enters-into-usa-department-of-defense-randd-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/recce-enters-into-usa-department-of-defense-randd-agreement</guid>
<pubDate>Mon, 28 Apr 2025 03:30:13 GMT</pubDate>
<description>Recce Enters into USA Department of Defense R&D Agreement</description>
</item>
<item>
<title>Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections</title>
<link>https://6ix.com/company/recce-ltd/news/recce-pharmaceuticals-receives-approval-additional-120000639</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/recce-pharmaceuticals-receives-approval-additional-120000639</guid>
<pubDate>Wed, 23 Apr 2025 12:00:00 GMT</pubDate>
<description>Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocolProgram enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer r</description>
</item>
<item>
<title>Entitlement Offer - Offer Booklet and Access Letter</title>
<link>https://6ix.com/company/recce-ltd/news/entitlement-offer-offer-booklet-and-access-letter</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/entitlement-offer-offer-booklet-and-access-letter</guid>
<pubDate>Tue, 22 Apr 2025 04:28:10 GMT</pubDate>
<description>Entitlement Offer - Offer Booklet and Access Letter</description>
</item>
<item>
<title>Phase II Clinical Trial Receives Additional Approval for DFI</title>
<link>https://6ix.com/company/recce-ltd/news/phase-ii-clinical-trial-receives-additional-approval-for-dfi</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/phase-ii-clinical-trial-receives-additional-approval-for-dfi</guid>
<pubDate>Tue, 22 Apr 2025 04:18:10 GMT</pubDate>
<description>Phase II Clinical Trial Receives Additional Approval for DFI</description>
</item>
<item>
<title>Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders</title>
<link>https://6ix.com/company/recce-ltd/news/recce-pharmaceuticals-announces-5-0-120000977</link>
<guid isPermaLink="true">https://6ix.com/company/recce-ltd/news/recce-pharmaceuticals-announces-5-0-120000977</guid>
<pubDate>Thu, 10 Apr 2025 12:00:00 GMT</pubDate>
<description>A$5.0 million commitment received from Australian-based private investorA$10.8 million Entitlement Offer at the same offer price as the placementFunds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026Directors intend to take up entitlements in part or in full in the Entitlement Offer SYDNEY, April 10, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), a leading developer of a new class of synthetic</description>
</item>
</channel>
</rss>